Wei Jia-Jing, Qiu Yu, Leng Mei, Chen Fu-Rui, Liang Mei-Yu, Deng Xi, Ma Rong-Ning, Hei Jing, Li-Ling Jesse, Gong Yan
Reproductive Medicine Centre, Sichuan Provincial Women's and Children's Hospital, The Affiliated Women's and Children's Hospital of Chengdu Medical College, Chengdu, Sichuan, China.
School of Clinical Medicine, Chengdu Medical College, Chengdu, Sichuan, China.
Front Endocrinol (Lausanne). 2025 Jun 10;16:1491259. doi: 10.3389/fendo.2025.1491259. eCollection 2025.
This study aimed to assess the impact of inoculation with the inactivated coronavirus disease 2019 (COVID-19) vaccine on the outcomes of fertilization and embryo transfer (IVF-ET).
From January 2021 to December 2022, patients undergoing their first cycle of IVF-ET at the Reproductive Medicine Center of Sichuan Provincial Women's and Children's Hospital were prospectively enrolled. Based on inoculation with inactivated COVID-19 vaccines before ovarian stimulation (OS) by a gonadotrophin-releasing hormone (GnRH) antagonist or agonist protocol, the patients were divided into the vaccinated group ( = 713) and the unvaccinated group ( = 545). The vaccinated group were sub-grouped based on the dose of inoculation (single dose, = 74; double dose, = 275; and triple dose, = 126) and the interval between the first inoculation and OS (<3 months, = 65; 3-6 months, = 123; and >6 months, = 287).
The rates of mature oocytes, normal fertilization, cleavage embryo, high-quality cleavage embryo, blastocysts, and high-quality blastocysts were not significantly different between the vaccinated and unvaccinated groups ( > 0.05). For fresh embryo transfer, the implantation rate (IR), the clinical pregnancy rate (CPR), the live birth rate (LBR), the gestational age at delivery, and the birth weight of infants were not significantly different between the two groups ( > 0.05). The IR, CPR, LBR, and birth weight of infants were not significantly different for both the dose and interval subgroups ( > 0.05).
Inactivated COVID-19 vaccines may not affect the outcomes of IVF-ET.
本研究旨在评估接种2019年冠状病毒病（COVID-19）灭活疫苗对体外受精-胚胎移植（IVF-ET）结局的影响。
前瞻性纳入2021年1月至2022年12月在四川省妇女儿童医院生殖医学中心接受首次IVF-ET周期治疗的患者。根据在使用促性腺激素释放激素（GnRH）拮抗剂或激动剂方案进行卵巢刺激（OS）前接种COVID-19灭活疫苗的情况，将患者分为接种组（n = 713）和未接种组（n = 545）。接种组根据接种剂量（单剂量，n = 74；双剂量，n = 275；三剂量，n = 126）以及首次接种与OS之间的间隔时间（<3个月，n = 65；3 - 6个月，n = 123；>6个月，n = 287）进行亚组划分。
接种组和未接种组之间成熟卵母细胞、正常受精、卵裂胚、优质卵裂胚、囊胚和优质囊胚的比率无显著差异（P>0.05）。对于新鲜胚胎移植，两组之间的着床率（IR）、临床妊娠率（CPR）、活产率（LBR）、分娩时的孕周和婴儿出生体重无显著差异（P>0.05）。剂量和间隔亚组的IR、CPR、LBR和婴儿出生体重均无显著差异（P>0.05）。
COVID-19灭活疫苗可能不会影响IVF-ET的结局。
